Persky, who oversaw the transition, stated that the board initially separated the roles to allow Shannon to focus exclusively on strategy and growth. Following his tenure as president and his earlier work as chief operating officer, the board concluded he possesses the necessary vision to unify the company's executive and oversight functions.
In section Market Quotes
Xeris Biopharma Consolidates Leadership Under CEO John Shannon
Nearly two years after taking the helm as chief executive, John Shannon will add the role of board chairman to his responsibilities at Xeris Biopharma starting July 1. He succeeds Marla Persky, who transitions to the position of lead independent director while remaining on the board.
Simultaneously, the board expanded its membership to eight with the addition of Dr. Nerissa Kreher. Currently the chief medical officer at Alltrna, Kreher brings two decades of industry experience, including past leadership roles at Entrada Therapeutics and AvroBio. Her appointment strengthens the board’s clinical and regulatory expertise as the company seeks to maintain its current trajectory.
Comments (0)
No comments yet. Be the first!